Janney Montgomery Scott
GLUE icon

Janney Montgomery Scott’s Monte Rosa Therapeutics GLUE Stock Holding History

Janney Montgomery Scott’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,315
Closed -$92K – 2736
2024
Q4 		$92K Buy
+13,315
New +$99.9K ﹤0.01% 2635

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janney Montgomery Scott's GLUE Position: Q1 2025 in Review

Janney Montgomery Scott sold out of Monte Rosa Therapeutics (GLUE) in Q1 2025, closing a stake of 13,315 shares — an estimated $92K sold.

Janney Montgomery Scott first reported a position in GLUE in Q4 2024 and held it in 1 quarter. The position peaked at $92K in Q4 2024. 105 funds tracked by Wall St. Rank hold GLUE as of Q1 2025.

  • Janney Montgomery Scott reported no remaining Monte Rosa Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Janney Montgomery Scott sold 13,315 Monte Rosa Therapeutics shares in Q1 2025, an estimated $92K.
  • Janney Montgomery Scott first reported a position in Monte Rosa Therapeutics in Q4 2024 and held it in 1 quarter.
  • Janney Montgomery Scott's Monte Rosa Therapeutics position peaked at $92K in Q4 2024.
  • 105 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2025.

Based on Janney Montgomery Scott's 13F filing for Q1 2025, filed 17 Apr 2025.